Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Penicillamine
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Penicillamine Capsules, USP (generic for Cuprimine®), a chelating agent recommended for the removal of excess copper in patients with Wilson's disease also in cystinuria, and in patients with severe, active rheumatoid arthritis.
Product Name : Pencillamine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Penicillamine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable